Twenty-Five Year Political Veteran Sam Myers, Jr. Named President of Direct Impact
24.9.2019 19:52:00 EEST | Business Wire | Press release
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Sam Myers, Jr., has been named President of Direct Impact (DI), the nation's leading grassroots campaign firm and member of BCW Group. Myers is based in Washington, D.C., and is charged with building DI’s industry-leading work in developing local market campaigns that drive communities to take action around various public affairs, public education and corporate reputation issues.
“I am thrilled that Sam will be leading DI,” said Chris Foster, President of BCW North America. “His more than two decades of political campaign experience and having served at the highest levels of government will be invaluable to clients that are navigating increasingly complex communications and legislative environments.”
Myers has served in two presidential administrations and worked on six presidential campaigns. From 2009 to 2017 he served in the Obama administration, in multiple leadership roles. For the U.S. Department of Education, his efforts in the Office of the Secretary and as head of Office of the White House Liaison helped put in place policies that supported narrowing the skills gap, job creation, healthy eating in schools and America’s College Promise.
Myers also spearheaded change management and communication for Department of Commerce’s move to a department-wide, enterprise services model. For the White House, he led delegations to the Vatican, UN General Assembly and Aspen Ideas Festival. In the Clinton administration, he served as an advance staffer for President Clinton and as a Defense Fellow at the U.S. Department of Defense.
Upon leaving the public sector in 2017, Myers transitioned to Brooklyn-based Huge, Inc., working in a series of roles, most recently Vice President for Partnerships and Development, where he developed thought leadership platforms around autonomous vehicles, aerospace, maternal health and the future of work; created partnerships at SXSW, CES and Cannes, among others; and drove strategic growth for Huge’s Washington, D.C. office and global business. He then served as a Senior Vice President for San Francisco-based The OutCast Agency, charged with expanding the agency’s Washington, D.C. presence.
“Across my 25 years in campaigns, politics and public affairs, the one constant I have seen is how powerful it is when companies and organizations connect with people on their own turf about the issues they care about the most,” said Myers. “I have watched and marveled at the extraordinary work DI has done in this area and I jumped at the chance to lead this great team.”
Myers’ campaign experience includes working on Hillary for America 2016; Obama for America; John Edwards for President 2008; Kerry Edwards 2004; Gore/Lieberman 2000; Clinton/Gore 1996 and founding DC based Myers Strategies in 2004, focused on effective messaging through national grass roots events.
About Direct Impact
Founded in 1988, Direct Impact (DI) is a wholly owned subsidiary of BCW and a member of the WPP family. DI is a premier grassroots communications firm, specializing in public affairs, public education and corporate reputation campaigns. DI provides a complete range of services essential to conducting successful localized campaigns, focusing on legislative battles as well as corporate branding challenges across the country. DI has led winning, community-driven campaigns for more than half of the Fortune 50, as well as major trade associations and coalitions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005903/en/
Contact information
Media: Catherine Sullivan
Phone: 212.601.3205
Email:
Catherine.Sullivan@bcw-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
